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Summary 
 
Corticobasal degeneration is a rare, progressive neurodegenerative disease and a 
member of the ‘parkinsonian’ group of disorders which also includes Parkinson’s 
disease, progressive supranuclear palsy, dementia with Lewy bodies, and multiple 
system atrophy. The most common initial symptom is limb clumsiness, usually 
affecting one side of the body, with or without accompanying rigidity or tremor. 
Subsequently, the disease affects gait and there is a slow progression to influence 
ipsilateral arms and legs. Apraxia and dementia are the most common cortical signs. 
Corticobasal degeneration can be difficult to distinguish from other parkinsonian 
syndromes, but if ocular signs and symptoms are present they may aid clinical 
diagnosis. Typical ocular features include increased latency of saccadic eye 
movements ipsilateral to the side exhibiting apraxia, impaired smooth pursuit 
movements, and visuo-spatial dysfunction especially involving spatial rather than 
object-based tasks. Less typical features include reduction in saccadic velocity, 
vertical gaze palsy, visual hallucinations, sleep disturbance, and an impaired 
electroretinogram. Aspects of primary vision such as visual acuity and colour vision 
are usually unaffected. Management of the condition to deal with problems of 
walking, movement, daily tasks, and speech problems is an important aspect of the 
disease.  
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Introduction 
 
Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disease 
affecting approximately 4.9-7.3/100,000 of the population.1 CBD largely affects 
individuals older than 60 years of age and death usually occurs within eight years of 
disease onset. The original description of the disease is based on three cases described 
as ‘corticodentatonigral degeneration achromasia’.2 The disorder has also been 
referred to as ‘corticoganglionic degeneration’3 but CBD remains the most popular 
descriptive term. Patients with a combination of clinical symptoms suggestive of the 
disorder are often referred to as having ‘corticobasal syndrome’ (CBS), while CBD is 
used strictly to describe cases verified at post-mortem.4  
 
Clinical diagnosis of CBD can be difficult as symptoms are variable and often 
resemble those of other types of neurodegenerative disorder. First, CBD is classified 
as a subtype of frontotemporal lobar degeneration (FTLD)5, the second most frequent 
form of cortical dementia of early-onset after Alzheimer’s disease (AD).6 Second, 
CBD is characterized by a cellular pathology consisting of abnormal cellular 
aggregations of the microtubule-associated protein (MAP) tau, and in this respect is 
similar to AD7 and progressive supranuclear palsy (PSP).8 Third, CBD is included 
within the ‘parkinsonian’ group of disorders, which includes Parkinson’s disease 
(PD)9, PSP8, dementia with Lewy bodies (DLB)10, and multiple system atrophy 
(MSA).11  
 
Visual signs and symptoms are frequently present in parkinsonian syndromes.8-11 
CBD can be difficult to distinguish from the other parkinsonian syndromes, but if 
ocular signs and symptoms occur they can aid clinical diagnosis. Hence, this review 
describes: (1) the major clinical and pathological features of CBD, (2) the visual signs 
and symptoms that have been identified, (3) the visual features which may help to 
distinguish CBD from other parkinsonian disorders, and (4) management of the 
disease.  
 
Clinical features  
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The onset of CBD is often sudden, patients exhibiting problems affecting cortical 
processing and motor function. The major clinical features include cortical signs such 
as apraxia and dementia12, parkinsonism, palsy, and myoclonus.13 The most common 
initial symptom is limb clumsiness affecting one side of the body, initially with or 
without accompanying rigidity or tremor.12,14,15 Subsequently, the disease spreads to 
affect gait and there is a slow progression to influence ipsilateral arms and legs.14  
 
The motor symptoms of CBD include parkinsonism, ‘alien hand syndrome’, and 
apraxia.4 The parkinsonism usually affects the extremities of the limb, is frequently 
asymmetric, and characterized by rigidity and bradykinesia. Alien hand syndrome is 
present in approximately 60% of affected individuals and is a failure to control the 
movement of a hand accompanied by a sensation that the hand is ‘foreign’ to the 
patient.16 The affected hand may also try to avoid specific external stimuli such as 
heat, cold, or touch and may exhibit an itching or prickling sensation. By contrast, the 
apraxia is characterized by an inability to repeat a specific movement of the hands and 
arms or an inability to carry out such a movement on command. ‘Limb-kinetic’ 
apraxia may also occur and is a dysfunction of fine movement control involving the 
hands.16 Myoclonus has also been observed in CBD and may result from the 
degeneration of an enhanced ‘long-loop reflex’ pathway17, rather than the classic 
‘cortical reflex’ myoclonus pathway.18  
 
Aphasia is present in some CBD patients and may involve disconnected speech and 
the omission of critical words.1 As the disease progresses, the patient may lose the 
ability to speak completely. These problems may be accompanied by irritability, 
depression, and cortical dementia which can result in confusion with AD.19 
Neuropsychological problems may also be present and include deterioration of 
‘global’ function, frontal lobe signs (‘dysexecutive syndrome’), and learning 
difficulties.20  
 
Neuropathology 
 
Gross features 
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Neuropathologically, CBD is characterised by a progressive and asymmetric cortical 
atrophy affecting the anterior cerebral cortex21, the fronto-parietal region17, and the 
superior temporal cortex.17 There is also atrophy of the basal ganglia, including the 
caudate nucleus22 and substantia nigra.23 Fig 1 illustrates a coronal section of the 
striatum and adjacent regions from a pathologically confirmed case of CBD showing 
enlarged lateral ventricles and atrophy of the caudate nucleus head, while the internal 
capsule, insula, putamen, and globus pallidus appear more normal. A summary of 
presenting features, motor symptoms, and brain regions affected in CBD compared 
with closely-related disorders such as PSP, PD, and AD is shown in Table 1. 
 
Histopathology 
 
There is a widespread neuronal and glial histopathology in CBD (Fig 2) affecting 
several different types of cell.24 Abnormalities of neurons include enlarged neuronal 
cell bodies25, thread-like dystrophic neurites26, and abnormal cellular protein 
aggregates, viz., ‘neuronal cytoplasmic inclusions’ (NCI).17 Pathology may also affect 
glial cells resulting in oligodendroglial inclusions27 and degeneration of astrocytes 
and their processes (‘astrocytic plaques’).28  
 
The typical distribution of the pathology in CBD is shown in Fig 3. First, pathology is 
frequently present in posterior frontal lobe anterior to the precentral gyrus but may be 
less severe in primary motor cortex.21 Second, NCI are frequent in temporal lobe, 
including the superior temporal gyrus and parahippocampal gyrus, and in the cornu 
ammonis sectors of the hippocampus, less abundant in frontal and parietal cortex, and 
only present at low density in the dentate gyrus.29 Third, NCI have been observed in 
association visual cortex (areas V2, V3).30 Fourth, enlarged neurons occur in a variety 
of regions including frontal cortex31, cingulate gyrus, superior frontal cortex, motor 
cortex, brainstem tegmentum, basal ganglia, thalamus, insula, claustrum, and 
amygdala.27,31  
 
Molecular pathology 
 
The pathology of CBD can be revealed using a variety of histological stains and 
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immunohistochemical procedures but the most sensitive are antibodies raised against 
the microtubule protein tau.32 Tau is encoded by the tau gene on chromosome 17, 
alternative splicing of exons 2, 3, and 10 resulting in six possible isoforms. Hence, tau 
resulting from encoding exon 10 is known as 4-repeat (4R) tau while tau lacking exon 
10 is referred as 3-repeat (3R) tau.33 CBD is characterized by 4R tau similar to that of 
PSP, and distinct from those tauopathies that consist largely of either 3R tau alone, 
such as Pick’s disease, or a mixture of 3R and 4R tau as in AD.34 Electron microscopy 
reveals that the tau-immunoreactive NCI are composed of paired helically-wound 
filaments, those of CBD being wider than in AD and with a longer periodicity.35 
Inclusions can also be found in oligodendrocytes in cortical white matter.36 These 
inclusions are often immunoreactive to tau, ubiquitin, heat shock protein, and alpha-
B-crystallin. Neuropil threads may also occur in the white matter of the spinal cord 
especially the anterior funiculus.23 -amyloid (A) protein deposits have also been 
observed in some cases of CBD resembling those found in AD.15,37 
 
Neuroimaging 
 
Magnetic resonance imaging (MRI) studies reveal the typical asymmetric cortical 
atrophy of CBD affecting posterior parietal and frontal regions together with atrophy 
of the corpus callosum.38 In addition, functional MRI (fMRI), utilizing a simple finger 
tapping task, has revealed lower levels of activity in parietal cortex, motor cortex, and 
supplementary motor cortex in CBD.38 Hypoperfusion in posterior frontal cortex and 
parietal cortex as well as abnormalities in thalamus, temporal cortex, basal ganglia, 
and pontocerebellar fibres has also been demonstrated using single photon emission 
computed tomography (SPECT).39 Consistent with post-mortem findings, fDOPA 
positron emission tomography (PET) reveals diminished dopamine uptake in the 
striatum. In addition, hypometabolism in the thalamus has been reported.40 Regional 
cerebral blood flow (rCBF) PET studies indicate that the clinically affected 
hemisphere has significantly reduced flow in posterior frontal and parietal cortices as 
well as in the thalamus and basal ganglia, while temporal and occipital lobes are 
essentially normal.22 In a particularly significant study, SPECT was used in 
association with mapping of anatomical areas to reveal hypoperfusion in visual areas 
V1 and V2 in CBD.41  
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Diagnosis 
 
Clinical and pathological diagnosis of CBS/CBD can be difficult as there is no 
specific clinical phenotype characteristic of the disease42 and the neuropathology of 
CBD overlaps with that of AD, other forms of FTLD43, the parkinsonian syndromes, 
and tauopathies.19 Diagnosis is further complicated by the presence of possible 
subtypes of CBD including those characterized by selective atrophy of: (1) fronto-
parietal, (2) exclusively frontal, and (3) superior temporal regions.17 Some 
neuropsychiatric features of CBD may be useful in diagnosis. Hence, CBD subjects 
are significantly better than those with AD on tests of immediate and delayed recall of 
verbal material while AD subjects are better on tests of praxis, finger tapping speed, 
and motor tasks generally.44 In addition, CBD subjects exhibit a wide range of 
cognitive and behavioural deficits which include in executive function and memory 
with non-specific language and visual spatial deficits whereas PSP subjects show 
apathy and impulsivity as consistent features.45 CBD is currently diagnosed using 
criteria recommended by the National Institute of Health (NIH) Office of Rare 
Diseases.42 A specific clinical phenotype is not required as diverse clinical symptoms 
may be present. Pathological diagnosis is based on the presence of: (1) tau-
immunoreactive NCI together with inclusions in oligodendrocytes, and the presence 
of astrocytic plaques, (2) NCI in the white and gray matter of cortical regions and 
striatum, and (3) neuronal loss in focal cortical areas and in the substantia nigra. 
 
Causes 
 
No specific cause of CBD has yet been established and few risk factors have been 
identified. Hence, the disease does not appear to be associated with stress, overwork, 
pregnancy, smoking, alcohol, diet, or social class. In addition, there is no evidence 
that it is caused by a virus or other infectious agent. Approximately 32% cases have a 
family history of the disease,46 familial cases being equally distributed between those 
exhibiting a primarily parkinsonian-type syndrome and those with cortical dementia. 
Mutations affecting the alternate-spliced exon 10 or the 5’ regulatory region of the tau 
gene can result in the typical tau-reactive inclusions characteristic of CBD.47 In 
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addition, a rare mutation of the tau gene has been reported in a single case of CBD.48 
Research also suggests a possible association between CBD and mutations of the 
progranulin49, and fused in sarcoma50 genes, which have also been implicated in 
FTLD.5 
 
Treatment 
 
There are no medications that can prevent or slow the development of CBD but 
various treatments are used to control symptoms. Hence, the parkinsonism is treated 
with levodopa/carbidopa, and rigidity specifically with baclofen.51  
Levodopa/carbidopa are usually less effective in CBD than in PD, however, but there 
may be some short-term improvement in rigidity and muscle stiffness. Limb dystonia 
is treated with botulinum toxin and myclonus with clonazepam and levetiracetam.52 
Memantine, a N-methyl-D-aspartate antagonist, and originally designed to reduce 
abnormal brain activity in AD, may have a similar affect in CBD.52 Nevertheless, 
effectiveness of this treatment is controversial and can result in side effects such as 
headache, dizziness, and shortness of breath. Visual side effects have been observed 
in association with Levodopa/carbidopa (mydriasis, miosis, blepharospasm, eyelid 
ptosis, diplopia, and reduced vision), baclofen (diplopia and visual hallucinations), 
levetiracetam (diplopia), and memantine (blurred vision, yellowing of eyes and skin). 
 
Visual signs and symptoms 
 
The major visual signs and symptoms described to date in CBD are summarized in 
Table 2. Caution is required in interpreting these data as: (1) vision has been studied 
less frequently in CBD than in other parkinsonian disorders8-11, (2) studies rely on a 
clinical diagnosis of CBS which can be difficult42, and (3) CBD is rare and therefore 
sample sizes in clinical studies often limited. 
 
Primary vision 
 
There are few data concerning changes in primary vision in CBD such as visual 
acuity. Nevertheless, patients with a parkinsonian syndrome often complain of poor 
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vision as the disease progresses, and such changes could be present in CBD.8-11 
Nevertheless, in CBD patients, in which difficulties involving visuospatial tasks or in 
reading ability have been reported, the patients denied that they had a significant 
visual loss.53 Photophobia appears to be significantly less frequent in CBD than in 
PSP.54  
 
Visual fields 
 
There have been few studies to date of visual field defects in any parkinsonian 
syndrome.8-11 However, in a single case of a lateralized cortical-subcortical dementia, 
CBD being the most likely diagnosis, there was left visual field inattention consistent 
with right hemisphere pathology.55 In addition, in six patients exhibiting posterior 
cortical atrophy (PCA), one of whom was diagnosed as CBD, a homonymous 
hemanopia, an inability to perceive more than a single object at a time 
(simultanagnosia), ‘Balint’s syndrome’, visual agnosia, facial recognition problems, 
and hemispatial neglect were present.56 Hence, an isolateral homonymous hemianopia 
may be suggestive of a diagnosis of PCA and therefore, of possible CBD.56  In 
addition, the highly lateralized pathology characteristic of CBD suggests that 
hemianopias could be more common in this disorder than in other parkinsonian 
syndromes. 
  
Eyelids and associated structures 
 
Apraxia of eyelid opening has been observed in CBD and results from defective 
coordination between the action of the orbicularis oculi and levator palpebrae 
muscles.57 Eyelid reflexes are impaired in several parkinsonian syndromes, especially 
in PSP8, and includes the ‘acoustic blink reflex’ and ‘acoustic startle reflex’, 
responses to a sudden and unexpected sound by a brief closing of the eye. In a single 
case diagnosed as severe CBD, the blink reflex was completely absent.58 
Blepharospasm is a common symptom in parkinsonian syndromes, especially in PSP 
and MSA, and is also present in CBD.59,60 Prominent blepharospasm in untreated 
patients with parkinsonism may suggest CBD.61 
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Eye movement  
 
One of the most consistent eye movement problems reported in CBD is an increase in 
saccadic latency, i.e., time from appearance of a target to the beginning of the 
saccadic response, as measured by electro-oculography (EOG).62,63 In a study which 
included six CBD and three atypical CBD cases, increased latency was ipsilateral to 
the side exhibiting the most significant apraxia.62 In addition, in a study of 10 CBD 
cases, increased latency was correlated with the degree of apraxia.64 In more atypical 
cases of CBD, vertical saccades and an early slowing of horizontal saccades have 
been reported but there was no increase in latency or early square-wave jerks.62 
Vertical saccade paralysis has been rarely observed in PD and CBD but is present in 
the majority of patients with PSP.64 By contrast, normal antisaccadic error rates 
(where eye movements are deliberately made in a direction opposite to the visual 
stimulus) have been recorded in CBD, a feature also demonstrated in PD65, but error 
rates are often increased in PSP.64 However, in a study of 15 cases of CBS, patients 
were impaired on antisaccadic tasks and were not able to spontaneously self-correct 
antisaccadic errors as well as controls.66 In addition, in more complex ‘mixed’ tasks, 
an increase in prosaccade and antisaccade error rates was reported in CBD.65 
 
In one of the largest visual studies of CBD to date, which involved 36 well-
characterized patients, smooth pursuit movements were commonly affected, a 
significant number of patients presenting with ‘jerky’ smooth pursuit movements, and 
in a small number of these patients, the range of movement was also restricted.14 
Decreased gain of smooth pursuit movements has also been observed in CBD.64 
Square-wave jerks have been reported in CBD.14,67,68 while abnormal optokinetic 
nystagmus also appears to be common.53,69  
 
Vestibulo-ocular reflex (VOR) 
 
The vestibulo-ocular reflex (VOR) is a reflex eye movement that stabilizes images on 
the retina during movements of the head. The ‘gain’ of the VOR is the ratio of the 
change in eye angle to head angle during a head turn. If the gain is impaired (ratio not 
equal to unity), head movements result in image motion on the retina and blurred 
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vision. The gain of the VOR in the dark may be cancelled by fixation. Both MSA and 
PSP patients show this cancellation compared with control cases and PD70, a response 
which could be related to cerebellar dysfunction. However, in CBD, in which there is 
less cerebellar pathology, there is little evidence for an effect on VOR. 
 
Electroencephalography (EEG) 
 
A slowing of general background activity and the appearance of focal slow waves 
have been recorded in CBD.71 Intermittent delta activity has also been recorded in 
both CBD and PSP, but focal slow waves appear to be characteristic only of CBD.71 
 
Evoked potentials (EP) 
 
Increased latency of the N200 and P300 components of the auditory evoked potential 
(AEP) and the N13 and N20 components of the somatosensory evoked potential 
(SEP)72 have been observed in CBD but there are no data on the corresponding visual 
evoked potential (VEP). However, there have been a number of studies of event-
related potentials in CBD, which elicit the ‘P300’ evoked response, believed to reflect 
orientation, attention, stimulus evaluation, and memory. These evoked responses may 
be associated with neural activity in the temporal lobe, prefrontal lobe, limbic system, 
and thalamus.73 Hence, in a study of the P300 event-related evoked response in 
patients with CBD using a visual stimulus73, the latency of the P300 was increased 
and mean reaction times were greater in CBD and in PSP than PD, the degree of the 
response being correlated with the extent of motor disability.73 ‘Giant’ cortical evoked 
potentials of high amplitude, recorded in a diverse range of conditions of myoclonic 
or cortical origin, have also been reported in CBD.74  
 
Complex visual functions 
 
In a case of typical PCA but presenting as ‘atypical CBD’, the patient exhibited a 
decline in spatial orientation and visual function which included fixation, optic ataxia, 
agraphia, acalculia, ideomotor apraxia, but with preserved colour matching.75 CBD 
patients may also exhibit difficulties in locating objects within a visual space.53 
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Hence, visuo-spatial dysfunction in CBD appears to be greater when it involves 
spatial rather than object-based tasks.76 These impairments could be related to 
pathological changes affecting the frontal lobe77 and visual association areas78, the 
latter suggesting that CBD should also be considered as a possible diagnosis in the 
presence of PCA. 
 
Sleep disorders 
 
Sleep disorders, which include excessive daytime sleeping, have been recorded in 
parkinsonian syndromes79 and are often caused by pathology affecting the regulation 
of the sleep/awake transitional period and respiratory function. Sleep behavioural 
disorder episodes often decrease in frequency but sleep becomes increasingly 
abnormal as disease develops.80 ‘Idiopathic rapid eye movement’ (iREM) sleep 
behaviour disorder has been observed in some parkinsonian syndromes, characterized 
by abnormal behaviour during sleep accompanied by iREM, probably resulting from 
neuronal loss in locus caeruleus and substantia nigra.81 So common is iREM in 
association with parkinsonism, that it is often regarded as a strong indicator of the 
presence of a parkinsonian syndrome. However, iREM appears rare in CBD, recent 
estimates suggesting an incidence of only 5%, and its absence could be a useful 
additional diagnostic feature.54 
 
Visual hallucinations 
 
Visual hallucinations have been reported in several parkinsonian disorders especially 
in individuals with significantly impaired visual acuity, severe cognitive 
impairment82, and Lewy body pathology. Hence, hallucinations occur most commonly 
in DLB and PD, but are less common in PSP and CBD.54,83,84 
 
Differential diagnosis of CBD 
 
A number of general features of the disease are suggestive of a diagnosis of CBD. 
First, degeneration in CBD affects both sensory and motor systems giving rise to a 
mixed ‘perceptual-motor’ syndrome, particularly characteristic of CBD.85 Second, 
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brain atrophy in CBD is often lateralized.86 Hence, in CBD, left side atrophy is 
usually greater than right side resulting in lateralized clinical signs, although bilateral 
atrophy can affect the superior parietal cortex (SPC) and striatum.86 There are also 
differences in the pattern of brain atrophy in CBD and PSP, greater midbrain atrophy 
affecting midbrain, pons, thalamus, and striatum in PSP while, atrophy, of dorsal 
frontal and parietal cortex is greater in CBD.86   
 
If visual signs and symptoms are present, they may provide additional support for a 
diagnosis of CBD. First, different combinations of oculomotor abnormalities are 
present in parkinsonian syndromes especially involving saccadic eye movement 
(Table 3). Hence, CBD is characterized by normal saccadic velocity but with 
abnormalities in saccadic gain which may distinguish CBD from PSP.68 Second, 
vertical saccade paralysis in PSP is also likely to distinguish this disorder from 
CBD.64 Nevertheless, clinicians should also be alert to intermediate and ‘atypical’ 
cases of CBD, in which vertical saccades may be present accompanied by an early 
slowing of horizontal saccades and the absence of square-wave jerks.62 Third, 
although changes in saccadic latency are common to the majority of parkinsonian 
disorders, increased saccadic latency ipsilateral to the side exhibiting apraxia is more 
likely to indicate CBD.62 However, saccadic eye movement dysfunction may be more 
similar in CBD, PD, and DLB, making these disorders more difficult to distinguish 
using these signs. Additional visual features that may aid a diagnosis of CBD are first, 
the presence of significant visuo-spatial dysfunction involving spatial rather than 
object-based tasks.76 Second, sleep disorders and visual hallucinations, unrelated to 
medication, are rare in CBD compared with PD and DLB, and their presence can 
often exclude CBD as a possible diagnosis.  
 
Management of the disease 
 
CBD can affect many aspects of life and a multidisciplinary approach to management 
and care is often necessary. Management of CBD involves physiotherapy to maintain 
mobility and prevent contractures, gait-training to improve mobility and decrease the 
risk of falls, and the use of social workers and occupational therapists to oversee the 
provision of equipment and home adaptation. An important problem in the clinical 
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management of the disease is that many subjects with CBD exhibit problems in 
communication resulting in their inability to ‘narrate a coherent story’.87 This defect is 
likely to result from impaired information integration, related to the degree of frontal 
and parietal lobe atrophy, and clinicians should be aware of this problem in 
communicating with patients. 
 
Visual deficits in parkinsonian-type syndromes are often important in influencing 
overall motor function. Visually, CBD can be regarded as an oculomotor apraxia 
accompanied by impairment of visuo-spatial processing and can be markedly 
debilitating.53 Hence, identifying and correcting the visual problems as far as possible 
can significantly reduce the chances that a patient will suffer a serious fall and 
improve quality of life. Optometrists can work in collaboration with the patient and 
health care providers to identify and manage the specific visual deficits of the patient. 
First, although significant decline in visual acuity has not been specifically 
demonstrated in CBD, it is typical of the parkinsonian syndromes in general8-11 and 
should be investigated in any suspected case of CBD. Second, visual fields should be 
tested as the pathology is often lateralized which could result in a hemianopia.55,56 
Third, although photophobia is less likely54 the external eye should be monitored as 
blepharospasm and possibly dry eye may be present, these features being an 
essentially treatable visual feature of parkinsonian syndromes.59-61 Artificial tears can 
be used to help dry eyes while blepharospasm has been treated successfully with 
botulinum toxin A injected at the junction of the preseptal and pretarsal parts of the 
levator palpebrae and orbicularis oculi muscles.57 Fourth, patients with difficulties in 
opening their eyelids may have ‘lid crutches’ fitted to spectacle frames that can hold 
the lids open. Fifth, CBD patients have a particular difficulty with saccadic eye 
movements and deficits in gaze control may influence ‘stepping behaviour’ which 
may increase the risk of trips or falls.88 Balance training in combination with eye 
movement and visual awareness exercises have been shown to improve gaze control 
in PSP89 and may also help in CBD.  Hence, patients can be referred to 
physiotherapists or occupational therapists. Sixth, CBD patients may have difficult in 
locating objects in visual space53,76 and strategies to improve object recognition in the 
home may be beneficial. In addition, to maximize visual acuity, cataract surgery, and 
appropriate refractive correction can improve motor outcomes and associated 
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therapies. 
 
Additional methods of managing CBD include cognitive stimulation which, through 
various activities and exercises, may improve memory, problem-solving, and 
language capability while physiotherapy can be used to strengthen muscles and 
improve posture.90 Dysphagia can be a problem in CBD and exercise may be 
employed to stimulate the nerves used to trigger the swallowing reflex. Dietary 
changes may be helpful which incorporate foods and liquids that are easier to 
swallow. Feeding tubes may be necessary in more severe cases especially where there 
is a risk of malnutrition and dehydration. In addition, general support and care are 
necessary as dystonia and immobility can lead to sores.52  
 
Conclusions 
 
CBD is a complex parkinsonian syndrome in which patients exhibit a variety of signs 
and symptoms affecting both sensory and motor function. The visual problems of 
CBD have been relatively little studied compared with the other parkinsonian 
syndromes8-11 as the condition is rare and difficult to clinically diagnose.42  The 
existing data suggest that the most important visual signs are increased latency of 
saccadic eye movements ipsilateral to the side exhibiting apraxia62, impaired smooth 
pursuit movements14, and visuo-spatial dysfunction especially involving spatial rather 
than object-based tasks76, but with relatively preserved primary vision. If ocular signs 
and symptoms are present, then they may aid differential diagnosis. The optometrist 
can play an important role in managing the disease both in ensuring that visual 
problems are corrected as far as possible and in referring patients to relevant health 
professionals. 
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Table 1. Comparison of presenting features, motor signs and symptoms, and brain 
regions affected in corticobasal degeneration (CBD), progressive supranuclear palsy 
(PSP), Alzheimer’s disease (AD), and Parkinson’s disease (PD) 
 
     Disorder 
_____________________________________________________________________ 
Feature CBD   PSP   AD   PD 
_____________________________________________________________________ 
 
Presentation Sudden onset  Variable  Insidious Insidious 
  Asymmetric limb Dystonic rigidity onset  onset 
clumsiness  Speech problems Short-term Impaired 
  No rigidity  Falls   memory mobility 
  or tremor     problems Autonomic 
          problems 
 
Motor  Parkinsonism  Gait and balance Mild  Akinesia 
symptoms Alien hand   affected    Rigidity 
  syndrome  Downward gaze   Tremor 
  Apraxia  dysfunction 
 
Brain regions Asymmetric  Greater midbrain General  Basal  
affected Frontal, parietal atrophy  cortical ganglia 
  temporal cortex Dorsal frontal    Later 
Basal ganglia  and parietal cortex   cortical 
   less affected 
_____________________________________________________________________ 
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Table 2. Summary of visual signs and symptoms in corticobasal degeneration (CBD) 
_____________________________________________________________________ 
Ocular function  Change  in  CBD    
_____________________________________________________________________ 
Primary vision Generally affected in parkinsonism syndromes8-11 but few data 
specific to CBD53  
Photophobia less frequent than in PSP54    
    
Visual fields  Hemianopia may be present due to lateralized pathology55,56
     
Eyelids   Apraxia of eyelid opening.57 Blink reflex may be affected.58 
   Blepharospasm often present61    
       
Saccadic eye  Increase in saccadic latency ipsilateral to side with ataxia562,63 
movements.  Early slowing of horizontal saccades in atypical case62 
Vertical saccade paralysis rare64 
   Increasing error rate in complex tasks64 
 
Smooth pursuit ‘Jerky’ smooth pursuit movements and restricted range 
movements  of movement14,64 
 
Square-wave jerks    Reported in CBD66,68 
 
Nystagmus Abnormal optokinetic nystagmus in a proportion of patients53,69
  
  
VOR   Normal in CBD70 
      
EEG Slowing of background activity and appearance of focal slow 
waves71        
   
Evoked potentials Abnormal auditory and somatosensory evoked potential72 
   Presence of ‘giant’ potentials74 
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Event-related  Abnormal P300 using visual stimuli72   
potentials  
 
Complex visual  Difficulty in locating objects within visual space53,76-78 
dysfunction    
  
Sleep disorder  Rare but iREM in approx. 5% of patients54   
          
Visual hallucinations Rare unrelated to medication54,82-84 
_____________________________________________________________________
Abbreviations: EEG = Electroencephalogram, iREM = Idiopathic rapid eye 
movement sleep disorder, PSP = Progressive supranuclear palsy, VEP = Visual 
evoked responses, VOR = Vestibulo-ocular reflex 
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Table 3. Comparison of saccadic eye movement parameters in corticobasal 
degeneration (CBD) with other parkinsonian syndromes (PD = Parkinson’s disease, 
PSP = Progressive supranuclear palsy (PSP), DLB = Dementia with Lewy bodies, 
MSA = multiple system atrophy (MSA) (? = Limited data) 
     Syndrome 
_____________________________________________________________________ 
Saccadic Parameter  CBD       PSP PD DLB             MSA 
_____________________________________________________________________ 
Velocity   -        +  - -  - 
 
Latency   +        +  + +  - 
 
Gain    +        +  + +  ? 
 
Vertical saccadic  -        +  - -  - 
paralysis 
 
Anti-saccade error rate -        +  + +  ? 
 
Complex saccadic tasks +        ?  + +  ? 
_____________________________________________________________________ 
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Titles to Figures 
 
Fig 1. Coronal section of the striatum of the brain from a pathologically confirmed 
case of corticobasal degeneration (CBD). The figure shows enlarged lateral ventricles 
(LV), atrophy of the head of the caudate nucleus (CN), but more normal internal 
capsule (IC), external capsule (EC), claustrum (Cl), and putamen (PuT)  
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Fig 2. Tau-immunoreactive pathology in the superior frontal cortex of a case of 
corticobasal degeneration (CBD) showing features used in pathological diagnosis. 
Arrowheads = Neuronal cytoplasmic inclusions (NCI), Arrow = Astrocytic plaque, 
star = Dystrophic neurite (tau immunohistochemistry, antibody AT8; haematoxylin) 
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. 
Fig 3. The areas of the brain likely to be affected by the pathology of corticobasal 
degeneration (CBD) (shown in bold in large font) (A = Amygdala, CG = Cingulate 
gyrus, CN = Caudate nucleus, GP = Globus pallidus, HC = Hippocampus, MC = 
Motor cortex, P = Pons, PC = Parietal cortex, PHG = Parahippocampal gyrus, Pu = 
Putamen, SFC = Superior frontal cortex, SN = Substantia nigra, STG = Superior 
temporal gyrus, Th = thalamus, VT = Ventral tegmentum. Other areas less likely to be 
affected in CBD  (in normal text and small font) (CB = Cerebellum, DG = Dentate 
gyrus, Hy = Hypothalamus, IC = Inferior colliculus, ION = Inferior olivary nucleus, 
LC = Locus careuleus, MB = Mamillary bodies, OB = Olfactory bulb, OC = Occipital 
cortex, PAG = Periaqueductal gray, PT = Pontine tegmentum, RH = Raphe nuclei, RF 
= Reticular formation, RN = Red nucleus, S = Septum, SC = spinal cord, STN = 
Subthalamic nucleus, SuC = Superior colliculus) superimposed on a two-dimensional 
model of the brain based on that of WJH Nauta and M Feirtag (1986) Fundamental 
Neuroanatomy. WH Freeman & Co. Hence the cerebral cortex is represented at the 
right of the diagram with the striatum and thalamus below. Midbrain and brain stem 
nuclei are at the left of the diagram 
 
 
 
